Preparations that should be given 12-hourly include MST Continus®, Morphgesic® SR, and Zomorph®. Preparations that should be given 24-hourly include MXL ®. With oral use in children:

CD2 (Schedule 2 (CD)) Zomorph 10mg modified-release capsules Ethypharm UK Ltd Show Cautionary and advisory labels. Label . 2 Warning: This medicine may make you sleepy. If this happens, do not drive or use tools or machines. Do not drink alcohol. Rhybudd: Gall y feddyginiaeth hon eich gwneud yn gysglyd.

Feb 26, 2025 · British National Formulary (BNF) Key information on the selection, prescribing, dispensing and administration of medicines.

Anticipatory prescribing and last days of life. Using an individualised approach, assess which medicines may be needed to manage symptoms likely to occur in the patient’s last days of life (such as morphine for pain and breathlessness; midazolam for agitation; levomepromazine or haloperidol for nausea and vomiting and delirium; or hyoscine butylbromide for …

Adult Initially 1 mg/hour, adjusted according to response, then increased in steps of up to 500 micrograms/hour, dose to be increased at intervals not more often than every 4 hours; usual dose 1–4 mg/hour, alternatively usual dose 15–60 micrograms/kg/hour, change infusion site every 12 hours and give during waking hours only (tolerance may occur unless there is …

Advice on the drug management of dental and oral conditions has been integrated into the main text. For ease of access, guidance on such conditions is usually identified by means of a relevant heading (e.g. Dental and Orofacial Pain) in the appropriate sections of the BNF. The following is a list of topics of particular relevance to dentists.

The content on the NICE BNF site (BNF) is the copyright of BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. By using BNF, you agree to the licence set out in the BNF Publications End User Licence Agreement .

The content on the NICE BNF site (BNF) is the copyright of BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. By using BNF, you agree to the licence set out in the BNF Publications End User Licence Agreement .

The content on the NICE BNF site (BNF) is the copyright of BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. By using BNF, you agree to the licence set out in the BNF Publications End User Licence Agreement .

Buprenorphine transdermal patches are used in the doses provided in the BNF for chronic pain, E but these may differ from those licensed. With oral use in children: Sublingual tablets not licensed for use in children under 6 years.